Table 1. HLA-C matched and mismatched NK donors and melanoma patients.
HLA-A | HLA-B | HLA-C | |||||||||
Allele 1 | Allele 2 | KIR-Ligand | Allele 1 | Allele 2 | KIR-Ligand | Allele 1 | Allele 2 | KIR-Lignad | |||
03 or 11 | Bw4 | C1 | C2 | ||||||||
Melanoma Mel008 | 2 | 2 | NO | 15 | 15 | NO | 3 | 3 | YES | NO | |
Mismatched | HD04 | 1 | 3 | YES | 37 | 57 | YES | 6 | 6 | NO | YES |
HD02 | 11 | 32 | YES | 41 | 57 | YES | 6 | 17 | NO | YES | |
HD20 | 30 | 31 | NO | 13 | 35 | YES | 4 | 6 | NO | YES | |
HD14 | 2 | 30 | NO | 41 | 44 | YES | 4 | 17 | NO | YES | |
Matched | HD07 | 32 | 33 | NO | 14 | 39 | NO | 8 | 12 | YES | NO |
HD12 | 2 | 2 | NO | 41 | 44 | YES | 7 | 16 | YES | NO | |
HD09 | 2 | 29 | NO | 14 | 44 | YES | 8 | 1 | YES | NO | |
Melanoma Mel10 | 1 | 1 | NO | 35 | 35 | NO | 4 | 4 | NO | YES | |
Mismatched | HD12 | 2 | 2 | NO | 41 | 44 | YES | 7 | 16 | YES | NO |
HD09 | 2 | 29 | NO | 14 | 44 | YES | 8 | 1 | YES | NO | |
HD07 | 32 | 33 | NO | 14 | 39 | NO | 8 | 12 | YES | NO | |
Matched | HD04 | 1 | 3 | YES | 37 | 57 | YES | 6 | 6 | NO | YES |
HD02 | 11 | 32 | YES | 41 | 57 | YES | 6 | 17 | NO | YES | |
HD20 | 30 | 31 | NO | 13 | 35 | YES | 4 | 6 | NO | YES | |
HD14 | 2 | 30 | NO | 41 | 44 | YES | 4 | 17 | NO | YES |
The table shows the identity of each of the two alleles of HLA-A, HLA-B and HLA-C for two melanoma patients (Mel008 and Mel10) and seven healthy NK donors (depicted as “HD” followed by a serial number). The table indicates whether one of the HLA-A alleles or HLA-B alleles is a KIR-ligand (highlighted in gray). Similarly, the table indicates whether each HLA-C is of C1 or C2 subgroup, effectively classifying all patients to homozygotes of C1 or C2, or C1–C2 heterozygotes (highlighted in gray). The table is arranged to demonstrate melanoma-NK pairs that are either HLA-C matched or mismatched.